Literature DB >> 949177

Cefatrizine (SK&F 60771), a new oral cephalosporin: serum levels and urinary recovery in humans after oral or intramuscular administration--comparative study with cephalexin and cefazolin.

P Actor, D H Pitkin, G Lucyszyn, J A Weisbach, J L Bran.   

Abstract

Cefatrizine (SK&F 60771), a new broad-spectrum cephalosporin, was administered in a 0.5-g dose either orally or intramuscularly to volunteers in a crossover study. After oral administration, the average peak serum levels were 5.6 and 22.1 mug/ml for cefatrizine and cephalexin, respectively. The serum half-life of cefatrizine appeared to be more extended than that of cephalexin. Urinary recovery of cefatrizine (35%) was approximately half that of cephalexin (68%) after oral administration. After intramuscular injection of 0.5 g, the average peak serum level of cefatrizine (12.0 mug/ml) was approximately one-fourth that of cefazolin (44.0 mug/ml). The serum half-life after intramuscular injection was 86 min for cefatrizine and 118 min for cefazolin. Urinary recovery was 45% of the intramuscularly administered dose, as compared with cefazolin, which was 74%.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 949177      PMCID: PMC429624          DOI: 10.1128/AAC.9.5.800

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro evaluation of BL-S640, a new oral cephalosporin antibiotic.

Authors:  G D Overturf; R L Ressler; P B Marengo; J Wilkins
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

2.  Comparative inhibitory activity of BL-S640 and two other cephalosporins.

Authors:  E Yourassowsky; E Schoutens; M P Vanderlinden
Journal:  J Antibiot (Tokyo)       Date:  1975-08       Impact factor: 2.649

3.  BL-S 640, a cephalosporin with a broad spectrum of antibacterial activity: properties in vitro.

Authors:  F Leitner; R E Buck; M Misiek; T A Pursiano; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

4.  BL-S640, a cephalosporin with a broad spectrum of antibacterial activity: bioavailability and therapeutic properties in rodents.

Authors:  F Leitner; D R Chisholm; Y H Tsai; G E Wright; R G Deregis; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

5.  Susceptibility of clinical isolates of Enterobacteriaceae to BL-S640, a new oral cephalosporin.

Authors:  C Watanakunakorn; T Bannister; C Glotzbecker
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

6.  Comparative serum levels and urinary recovery of cefazolin, cephaloridine, and cephalothin in man.

Authors:  M M Cahn; E J Levy; P Actor; J F Pauls
Journal:  J Clin Pharmacol       Date:  1974-01       Impact factor: 3.126

7.  Comparative serum levels and protective activity of parenterally administered cephalosporins in experimental animals.

Authors:  L R Fare; P Actor; C Sachs; L Phillips; M Joloza; J F Pauls; J A Weisbach
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

8.  Laboratory studies with cefatrizine (SK + F 60771), a new broad-spectrum orally-active cephalosporin.

Authors:  P Actor; J V Uri; L Phillips; C S Sachs; J R Guarini; I Zajac; D A Berges; G L Dunn; J R Hoover; J A Weisbach
Journal:  J Antibiot (Tokyo)       Date:  1975-08       Impact factor: 2.649

  8 in total
  3 in total

1.  Interethnic differences of PEPT2 (SLC15A2) polymorphism distribution and associations with cephalexin pharmacokinetics in healthy Asian subjects.

Authors:  Rui Liu; Audrey May Yi Tang; Yen Ling Tan; Lie Michael George Limenta; Edmund Jon Deoon Lee
Journal:  Eur J Clin Pharmacol       Date:  2008-09-03       Impact factor: 2.953

Review 2.  The cephalosporins: activity and clinical use.

Authors:  A J Weinstein
Journal:  Drugs       Date:  1980-08       Impact factor: 9.546

3.  Iodine-mediated C-N and N-N bond formation: a facile one-pot synthetic approach to 1,2,3-triazoles under metal-free and azide-free conditions.

Authors:  Geeta Sai Mani; Kavitha Donthiboina; Siddiq Pasha Shaik; Nagula Shankaraiah; Ahmed Kamal
Journal:  RSC Adv       Date:  2019-08-28       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.